Reference SummaryReitmair AH, Cancer Res 1996 Jul 1;56(13):2922-6
Title |
MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. | ||||||||||
Authors |
Reitmair AH; Cai JC; Bjerknes M; Redston M; Cheng H; Pind MT; Hay K; Mitri A; Bapat BV; Mak TW; Gallinger S | ||||||||||
Journal |
Cancer Res | ||||||||||
Volume |
56 | ||||||||||
Issue |
13 | ||||||||||
Year |
1996 | ||||||||||
Pages |
2922-6 | ||||||||||
Abstract |
Accelerated intestinal tumorigenesis is probable in hereditary nonpolyposis colorectal cancer, a condition associated with germ line DNA mismatch repair (MMR) gene defects, and is believed to be caused by rapid accumulation of replication errors in critical genes, such as the APC (adenomatous polyposis coli) tumor suppressor gene. To study the potential contribution of MMR genes to accelerated intestinal tumorigenesis, we crossed the Min mouse, heterozygous for a germ line mutation of Apc, with an MMR gene (Msh2)-deficient mouse. MSH2 deficiency resulted in the development of many colonic aberrant crypt foci, as well as reduced survival of the mice, secondary to both a greater number and more rapidly developing adenomas. The mechanism of inactivation of the wild-type Apc allele depended on MSH2 status. In the presence of functional MSH2, all tumors demonstrated loss of heterozygosity. In contrast, whereas all adenomas were APC negative by immunostaining, only 5 of 34 adenomas from Apc+/-/Msh2-/- mice demonstrated loss of heterozygosity of the wild-type Apc allele, suggesting that somatic Apc mutations are responsible for the additional tumors. These findings provide evidence for the important role of MMR genes in accelerated intestinal tumorigenesis, thus supporting more aggressive surveillance strategies to prevent colorectal cancer in hereditary nonpolyposis colorectal cancer. | ||||||||||
Links |
J:75393 – MGI References 8674041 – National Library of Medicine/PubMed |
||||||||||
Strain Notes
|
Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
---|---|---|---|---|---|
B6;129P2-ApcMin/+ | Intestine - Large Intestine - Colon adenoma | Intestine - Large Intestine - Colon |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak/+ | Intestine - Large Intestine - Colon adenoma | Intestine - Large Intestine - Colon |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak | Intestine - Large Intestine - Colon adenoma | Intestine - Large Intestine - Colon |
observed - 67 |
||
B6;129P2-ApcMin/+ | Intestine - Large Intestine - Colon foci - aberrant crypt (ACF) | Intestine - Large Intestine - Colon |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak/+ | Intestine - Large Intestine - Colon foci - aberrant crypt (ACF) | Intestine - Large Intestine - Colon |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak | Intestine - Large Intestine - Colon foci - aberrant crypt (ACF) | Intestine - Large Intestine - Colon |
very high |
||
C57BL/6J-ApcMin/+ | Intestine - Large Intestine adenoma | Intestine - Large Intestine |
observed |
||
B6;129P2-ApcMin/+ | Intestine - Small Intestine adenoma | Intestine - Small Intestine |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak/+ | Intestine - Small Intestine adenoma | Intestine - Small Intestine |
observed |
||
B6;129P2-ApcMin/+ Msh2tm1Mak | Intestine - Small Intestine adenoma | Intestine - Small Intestine |
observed |
||
C57BL/6J-ApcMin/+ | Intestine - Small Intestine adenoma | Intestine - Small Intestine |
observed |
||
B6;129P2-ApcMin/+ | Intestine carcinoma | Intestine |
0 |
||
B6;129P2-ApcMin/+ Msh2tm1Mak/+ | Intestine carcinoma | Intestine |
0 |
||
B6;129P2-ApcMin/+ Msh2tm1Mak | Intestine carcinoma | Intestine |
0 |
||
B6;129P2-ApcMin/+ Msh2tm1Mak | Leukocyte lymphoma | Thymus |
29 |